Anti-immunoglobulin responses to IgG, F(ab′)2, and Fab botulinum antitoxins in mice

Immunopharmacology and Immunotoxicology

Volumn 25, Issue 3, 2003, Pages 397-408

  Mayers, Carl N ^a   Veall, Shelagh ^a   Bedford, Richard J ^a   Holley, Jane L ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Anti antibody response; Antitoxin; Botulinum; Botulism; F(ab )2; Fab; HAMA response; Toxin

Indexed keywords

BOTULINUM ANTISERUM; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; GOAT; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHEEP; TH2 CELL;

ANIMALS; ANTIBODIES; BOTULINUM ANTITOXIN; GOATS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; SHEEP; TIME FACTORS;

ANIMALIA; CAPRA HIRCUS; OVIS ARIES;

EID: 0141788115     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.1081/IPH-120024507     Document Type: Article

References (14)

1. Mayers, C.N.; Holley, J.L.; Brooks, T. Antitoxin therapy for botulinum intoxication. Rev. Med. Micro. 2001, 12 (1), 29-37.
2. Bardenwarper, H.W. Serum neuritis from tetanus antitoxin. JAMA 1962, 179, 763-766.
3. Black, R.E.; Gunn, R.A. Hypersensitivity reactions associated with botulinal antitoxin. Am. J. Med. 1980, 69, 567-570.
4. Dillman, R.O. Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunoconj. Radiopharm. 1990, 3, 1-15.
5. Blumenthal, R.D.; Sharkey, R.M.; Synder, D.; Goldenberg, D.M. Reduction by antiantibody administration of the radiotoxicity associated with 131I-labelled antibody to carcinoembryonic antigen in cancer radioimmunotherapy. J. Natl. Cancer Inst. 1989, 81 (3), 194-199.
6. Kashmiri, S.V.; Iwahashi, M.; Tamura, M.; Padlan, E.A.; Milenic, D.E.; Schlom, J. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Crit. Rev. Oncol. Hematol. 2001, 38 (1), 3-16.
7. Kricka, L.J. Human anti-animal antibody interferences in immunological assays. Clin. Chem. 1999, 45 (7), 942-956.
8. Hibbs, R.G.; Weber, J.T.; Corwin, A.; Allos, B.M.; Abd el Rehim, M.S.; Sharkawy, S.E.; Sam, J.E.; McKee, J.T. Experience with the use of an investigational F(ab′)2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin. Infect. Dis. 1996, 23 (2), 337-340.
9. Smith, T.W.; Lloyd, B.L.; Spicer, N.; Haber, E. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clin. Exp. Immunol. 1979, 36, 384-396.
10. Kearns, G.L.; Moss, M.M.; Clayton, B.D.; Hewett, D.D. Pharmacokinetics and efficacy of digoxin specific Fab fragments in a child following massive digoxin overdose. J. Clin. Pharmacol. 1989, 29, 901-908.
11. Smith, T.W. Review of clinical experience with digoxin immune Fab (ovine). Am. J. Emer. Med. 1991, 9, 1-6.
12. Sjostrom, L.; Al-Abdulla, I.H.; Rawat, S.; Smith, D.C.; Landon, J. A comparison of ovine and equine antivenoms. Toxicon 1994, 32 (4), 427-433.
13. Kirkpatrick, C.H. Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. Am. J. Emerg. Med. 1991, 9, 7-10.
14. Hatheway, C.H.; Snyder, J.D.; Seals, J.E.; Edell, TA.; Lewis, G.E. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J. Infect. Dis. 1984, 150 (3), 407-412.